{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/allergic-rhinitis/prescribing-information/intranasal-decongestants/","result":{"pageContext":{"chapter":{"id":"5102b868-dccf-58c1-b6c7-3a59a24c6602","slug":"intranasal-decongestants","fullItemName":"Intranasal decongestants","depth":2,"htmlHeader":"<!-- begin field dcc91941-6530-43a4-8e23-90304662cb56 --><h2>Intranasal decongestants</h2><!-- end field dcc91941-6530-43a4-8e23-90304662cb56 -->","summary":"","htmlStringContent":"<!-- begin item 5acdbc46-f343-4d5c-97dd-14a6ac5d7bff --><!-- end item 5acdbc46-f343-4d5c-97dd-14a6ac5d7bff -->","topic":{"id":"e84371ef-9d30-56df-8358-1520fb2c324f","topicId":"0473d89c-2999-40d1-911f-d265b4bd3942","topicName":"Allergic rhinitis","slug":"allergic-rhinitis","lastRevised":"Last revised in September 2018","chapters":[{"id":"5fa28a05-233b-5de6-aee8-ea0327f3c7d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ea1f0c07-a5f8-599b-9b96-71ef8590b2a6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"99b142c6-9593-51c7-9c86-7c8a537a3b8c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67cd9666-b198-574f-9fbf-cd740a7d8c3e","slug":"changes","fullItemName":"Changes"},{"id":"7d544db5-f3b7-5709-a2ae-076455d76d20","slug":"update","fullItemName":"Update"}]},{"id":"392391e3-b09a-5cab-ae2a-040eb039abd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"292568d8-a1f5-5b8f-a13d-f3c014fa8e95","slug":"goals","fullItemName":"Goals"},{"id":"2f7129b7-e08b-5e5f-997c-4b661ce0a778","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8062582a-18e3-58d5-a8cb-f9689e259444","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1e562233-ae40-5755-abc7-71551f4cea02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ccab909c-169d-52aa-ac0a-9d425f89a99c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37d61d5d-e2f1-58ef-9c6a-27c4011784f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84432cb8-00ce-599e-9e05-3493755dacd6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f59296af-8e0a-509d-b8f3-692efd2bdb92","slug":"definition","fullItemName":"Definition"},{"id":"37020833-afb2-529a-975a-1f1a7a5db2ef","slug":"causes","fullItemName":"Causes"},{"id":"962f75f0-d73d-5c7c-aaf4-d08fc672e6be","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ab993d04-4c7b-59cd-9e56-2e0ef7fdc9db","slug":"complications","fullItemName":"Complications"},{"id":"68b348fd-2864-5da4-8687-6d8c25004f1b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"80c9e7d3-3315-55b9-98fb-2261b95a1b5c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3cc3ef09-2238-5504-8781-48914ad6a4c9","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5a3f0e38-3f88-5049-beaa-f4cb26499dc6","slug":"assessment","fullItemName":"Assessment"},{"id":"5bd413c7-0398-5b71-acad-a5699c7c703b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9b8b1dfa-dfda-5292-a329-64d2c435a006","fullItemName":"Management","slug":"management","subChapters":[{"id":"a132cc60-bb1b-5679-8eda-db080a1e772a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"760f3c4d-0984-5865-acbe-65d470f66518","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a47a2aa5-0821-5bf5-987b-2397ac2c982f","slug":"intranasal-antihistamines","fullItemName":"Intranasal antihistamines"},{"id":"449809a3-a714-573e-a21f-8e4295eb984e","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"5507fb81-aa18-5a21-b619-8db3c3c78e80","slug":"intranasal-cromones","fullItemName":"Intranasal cromones"},{"id":"5102b868-dccf-58c1-b6c7-3a59a24c6602","slug":"intranasal-decongestants","fullItemName":"Intranasal decongestants"},{"id":"623ba003-b473-5be2-bc25-e438f1500f7c","slug":"intranasal-anticholinergics","fullItemName":"Intranasal anticholinergics"},{"id":"c871daa0-d649-59f1-b13c-79ab64e7083e","slug":"oral-leukotriene-receptor-antagonists","fullItemName":"Oral leukotriene receptor antagonists"}]},{"id":"f3877d58-da5a-5655-8752-49e87f3a410b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"87371e7f-8741-54ef-9af6-339f8f0b9285","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"318f5be9-46cf-5fb9-b28c-7ebb4a901904","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49c3da95-9d4f-5a93-a7ca-e71965fcb981","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"33a2085c-95d6-5004-8f1f-50a08684c638","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b1a0d4a-fd5e-5b81-9293-5b2f004871cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"735b627c-7d7e-58b8-8196-b4972220342b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"92889a85-b6e7-58f3-9f09-eae6ca76386c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"760f3c4d-0984-5865-acbe-65d470f66518","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"26fa2353-595f-56c9-ab26-cb7befe77dc6","slug":"dose-regimens","fullItemName":"Dose regimens","depth":3,"htmlHeader":"<!-- begin field 95fcb797-a91c-4eb8-85c2-a96c00ae47bb --><h3>Dose regimens</h3><!-- end field 95fcb797-a91c-4eb8-85c2-a96c00ae47bb -->","summary":"","htmlStringContent":"<!-- begin item 25c3361c-39a0-4418-a613-a96c00ae4771 --><!-- begin field cd90449e-2ff8-44f4-a64c-a96c00ae47bb --><ul><li><strong>Ephedrine hydrochloride 0.5% nasal drops are licensed for the management of nasal congestion in adults and children aged 12 years and over:</strong><ul><li>For children aged 12–17 years — apply 1–2 drops up to four times a day as required for a maximum of seven days, to be instilled into each nostril.</li></ul></li><li><strong>Xylometazoline hydrochloride nasal drops or spray are licensed for the management of nasal congestion in adults and children over 6 years of age,</strong> depending on the person's age:<ul><li>For children aged 6–11 years — 1–2 nasal drops applied 1–2 times a day as required for a maximum duration of five days, 0.05% solution to be administered into each nostril.</li><li>For children aged 12–17 years and adults — 2–3 drops applied 2–3 times a day as required for a maximum duration of seven days, 0.1% solution to be administered into each nostril; or one nasal spray applied 1–3 times a day as required for a maximum duration of seven days, to be administered into each nostril.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field cd90449e-2ff8-44f4-a64c-a96c00ae47bb --><!-- end item 25c3361c-39a0-4418-a613-a96c00ae4771 -->","subChapters":[]},{"id":"3d11cd72-ed59-5f29-be17-ab1ed587199a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 90271f6d-c457-4c9d-8a87-8826e9e83cc7 --><h3>Contraindications and cautions</h3><!-- end field 90271f6d-c457-4c9d-8a87-8826e9e83cc7 -->","summary":"","htmlStringContent":"<!-- begin item 662305c5-912c-48f2-b779-89b356d9da20 --><!-- begin field 156a2eaf-0160-42b2-bc06-28d40ce329f1 --><ul><li><strong>Prescribe intranasal ephedrine and xylometazoline with caution to people with:</strong><ul><li>Diabetes mellitus.</li><li>Hypertension.</li><li>Hyperthyroidism.</li><li>Cardiovascular disease.</li><li>Angle-closure glaucoma and prostatic hyperplasia or enlargement (risk of acute urinary retention in men) — for xylometazoline hydrochloride.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field 156a2eaf-0160-42b2-bc06-28d40ce329f1 --><!-- end item 662305c5-912c-48f2-b779-89b356d9da20 -->","subChapters":[]},{"id":"52d7fd63-2239-5e3d-b57b-6fc2e21d50b6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7d9b1335-f9d7-4341-a9d2-851d6dba858d --><h3>Adverse effects</h3><!-- end field 7d9b1335-f9d7-4341-a9d2-851d6dba858d -->","summary":"","htmlStringContent":"<!-- begin item b05e5772-1e37-4743-b21f-26b60afa25f2 --><!-- begin field 6265d572-d124-4260-8ee8-6def83f62371 --><ul><li><strong>Possible adverse effects of intranasal ephedrine and xylometazoline include:</strong><ul><li>Long-term use of intranasal decongestants is associated with rebound nasal congestion upon withdrawal, which in turn encourages further use that can result in hypertrophy of the nasal mucosa (so-called 'rhinitis medicamentosa'). In addition, tolerance with diminished effect may be seen after excessive use.</li><li>Headache, nausea, transient visual disturbances, local irritation and dryness.</li><li>Hallucinations, restlessness, and sleep disturbance in small children (with xylometazoline hydrochloride use).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field 6265d572-d124-4260-8ee8-6def83f62371 --><!-- end item b05e5772-1e37-4743-b21f-26b60afa25f2 -->","subChapters":[]},{"id":"ce4d1d97-53d2-5a9c-a909-ca1d7934f69f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d748be99-559d-4adc-b477-a96800dc7cdb --><h3>Drug interactions</h3><!-- end field d748be99-559d-4adc-b477-a96800dc7cdb -->","summary":"","htmlStringContent":"<!-- begin item 201b3c65-3398-4468-881d-a96800dc7c9e --><!-- begin field 7f2d85c6-4792-471f-9817-a96800dc7cdb --><ul><li><strong>Possible drug interactions with intranasal ephedrine hydrochloride include:</strong><ul><li><strong>The manufacturer advises that prescribers avoid:</strong></li><li>Amitriptyline — amitriptyline is predicted to decrease the effects of ephedrine.</li><li>Clomipramine — clomipramine is predicted to decrease the effects of ephedrine.</li><li>Dosulepin — dosulepin is predicted to decrease the effects of ephedrine.</li><li>Doxepin — doxepin is predicted to decrease the effects of ephedrine.</li><li>Imipramine — imipramine is predicted to decrease the effects of ephedrine.</li><li>Lofepramine — lofepramine is predicted to decrease the effects of ephedrine.</li><li>Nortriptyline — nortriptyline is predicted to decrease the effects of ephedrine.</li><li>Rasagiline — rasagiline is predicted to increase the risk of a hypertensive crisis when given with ephedrine.</li><li>Selegiline — selegiline is predicted to increase the risk of a hypertensive crisis when given with ephedrine.</li><li><strong>In </strong><strong>addition,</strong><strong> the manufacturer </strong><strong>advises</strong><strong> that prescribers avoid the following medications in children:</strong></li><li>Aminophylline — ephedrine increases the risk of side-effects when given with aminophylline. </li><li>Theophylline — ephedrine increases the risk of side-effects when given with theophylline.</li></ul></li><li><strong>Possible drug interactions with intranasal xylometazoline hydrochloride include:</strong><ul><li>Rasagiline — rasagiline is predicted to increase the risk of a hypertensive crisis when given with xylometazoline. Manufacturer advises avoid.</li><li>Selegiline — selegiline is predicted to increase the risk of a hypertensive crisis when given with xylometazoline. Manufacturer advises avoid.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field 7f2d85c6-4792-471f-9817-a96800dc7cdb --><!-- end item 201b3c65-3398-4468-881d-a96800dc7c9e -->","subChapters":[]},{"id":"de60e576-7ac0-5066-b7b9-3a432dde1c0d","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 21cd1cbc-3777-48be-949f-a96c00b23951 --><h3>Pregnancy and breastfeeding</h3><!-- end field 21cd1cbc-3777-48be-949f-a96c00b23951 -->","summary":"","htmlStringContent":"<!-- begin item 882e5753-fb54-4498-b3ee-a96c00b238f2 --><!-- begin field 7e598131-7550-4b76-ac64-a96c00b23951 --><h4>Pregnancy</h4><ul><li>The manufacturer advises to avoid the use of intranasal ephedrine and xylometazoline during pregnancy.</li></ul><h4>Breastfeeding</h4><ul><li>Ephedrine is present in breast milk and the manufacturer advises avoid — irritability and sleep disturbance reported.</li><li>There is no specific information regarding the safety of intranasal xylometazoline in breastfeeding, and the manufacturer advises caution.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field 7e598131-7550-4b76-ac64-a96c00b23951 --><!-- end item 882e5753-fb54-4498-b3ee-a96c00b238f2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}